AAMI TIR48 : 2015
Superseded
View Superseded by
QUALITY MANAGEMENT SYSTEM (QMS) RECOMMENDATIONS ON THE APPLICATION OF THE U.S. FDAS CGMP FINAL RULE ON COMBINATION PRODUCTS
English
01-01-2015
05-21-2021
Glossary of equivalent standards
Committee representation
Introduction
1 Scope
2 Applying CGMPs in Accord with FDA's Final Rule
for Combination Products (21 CFR Part 4)
3 Considerations in transitioning
to 'Streamlined Approach'
4 Application of Design Controls and
Management for a Combination Product
Annex A - Terminology
Bibliography
Gives recommendations on the application of CGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissue based products during development and marketing of combination products (drug-device, biologic-device, drug-biologic, or drug-device-biologic), in accordance with the FDA's final rule (21 CFR Part 4; 78 FR 4307, 2013-hereafter 'The Rule' or 'FDA's Final Rule').
| DocumentType |
Standard
|
| Pages |
28
|
| PublisherName |
Association for the Advancement of Medical Instrumentation
|
| Status |
Superseded
|
| SupersededBy |
A newer version of this standard is available.
View Current Edition